Clinical trial tests multiple targeted agents for treatment of non-Hodgkin lymphoma
Lymphoma, Non-Hodgkin, Adult, Stage III
Photo courtesy of NCI Visuals Online
Patients with relapsed/refractory aggressive non-Hodgkin lymphoma may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Non-Hodgkin lymphoma(NHL) is a fast-growing cancer that affects B cells, a type of white blood cell that is carried through the body by the lymphatic system. B cells fight infection as part of the immune system. NHL occurs when B cells start to multiply out of control. “Relapsed” NHL refers to disease that responded to initial treatment but then recurred. “Refractory” NHL refers to disease that did not respond to initial treatment. There are very few effective therapies for either type of NHL. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading CCR’s participation in a trial to test the safety and effectiveness of two combination treatments for relapsed/refractory NHL. In one study arm, patients will receive acalabrutinib plus AZD9150. Acalabrutinib inhibits an enzyme that helps B cells grow and multiply. AZD9150 inhibits a protein that helps to regulate cell growth and division. The second study arm will receive acalabrutinib plus AZD6738. AZD6738 inhibits a protein that helps damaged DNA repair itself. The study team wants to see if either combination can slow or stop the growth of lymphoma cells.
Clinicaltrials.gov identifier: NCT03527147
NCI Protocol ID: NCI-18-C-0130
Official Title: PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.Mon, 10/01/2018